On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus's casdatifan (an investigational HIF-2α inhibitor) with Summit's ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of this combination in clear cell renal cell carcinoma (ccRCC), including first-line metastatic disease. Arcus CEO Terry Rosen highlighted the opportunity to establish a well-tolerated, TKI-sparing regimen that could prolong survival and serve as a first-line backbone therapy.
Under the agreement, Summit Therapeutics will supply ivonescimab while Arcus sponsors and conducts the study as a new cohort in its ARC-20 platform, with both sharing costs and retaining commercial rights. Initial data is expected by mid-2027. To strengthen its broader casdatifan strategy, Arcus also inked a clinical supply pact with AVEO Oncology on July 22.
Comparing Q2 2026 financial performance, both clinical-stage biotechs maintain robust liquidity, but Arcus currently holds stronger revenue generation and a longer operating runway. Arcus Biosciences, Inc. reported Q2 2026 revenue of $41 million (down from $160 million in Q2 2025 due to a prior-year catch-up) and a net loss of $91 million. It ended the quarter with $775 million in cash, cash equivalents, and marketable securities, providing cash runway into at least the second half of 2028.
In contrast, Summit Therapeutics Inc. reported no product revenue for Q2 2026 and recorded a GAAP net loss of $215.7 million. Summit closed the quarter with $690.7 million in cash and short-term investments, supported heavily by $230.8 million raised via its ATM equity facility. While both carry zero long-term debt, RCUS is doing better financially due to lower quarterly net losses, established collaboration revenue, and an extended runway without relying as heavily on continuous ATM dilution Arcus Biosciences' bull case centers on casdatifan, which is demonstrating potential as a backbone HIF-2α inhibitor.
Following the company's second-quarter results, Wedbush raised its price target to $43 from $41 while maintaining an Outperform rating on August 6, citing aggressive program expansion ahead of pivotal clinical readouts expected in October. However, the bear case is that revenue can fluctuate significantly based on partner milestone payments, while the wind-down of domvanalimab's Phase 3 trials reduces pipeline diversification and increases reliance on other clinical programs. Summit Therapeutics' bull case is supported by ivonescimab, which remains one of the more promising PD-1/VEGF bispecific antibodies in development.
Momentum strengthened on August 5 when Summit announced an expansion of ivonescimab's development program into urothelial carcinoma, or bladder cancer, potentially broadening the drug's commercial opportunity. On the downside, Summit continues to face substantial cash burn, reporting a $215.7 million GAAP net loss in the second quarter. With no commercial revenue, the company may need to continue issuing shares to fund development, creating a risk of significant equity dilution.
Extract — continue reading at the source.
